Researchers at Leiden University Medical Center (LUMC), in collaboration with Erasmus MC and the Oncode Institute, have developed a novel vaccine targeting non-small cell lung cancer (NSCLC). This vaccine aims to expose cancer cells that have evaded the immune system, potentially enhancing the effectiveness of immunotherapy treatments.
In a preliminary clinical study involving 26 patients with advanced NSCLC, the vaccine demonstrated safety and elicited an immune response in over 80% of participants. The vaccine works by training immune cells to recognize a specific protein, TEIPP, present only on cancer cells that have become invisible to the immune system. By making these hidden cells detectable again, the immune system can more effectively target and destroy them.
While these initial results are promising, further research is needed to determine the vaccine’s impact on tumor reduction and patient survival. Future studies will explore optimal dosing schedules and the potential benefits of combining the vaccine with existing immunotherapies.
This approach highlights the collaborative efforts within the Leiden Bio Science Park to advance cancer treatment through innovative research.
Read more here: https://www.lumc.nl/actueel/2025/vaccin-tegen-longkanker/
University Campus Spui, Leiden University’s fourth location in The Hague, is about to open its doors. The transformation of the former V&D department store into a university...
Biotech start-up Bionomic from Oegstgeest (South Holland) won the Innovation Promise Award on Friday during the twentieth edition of the announcement of the KVK Innovation Top...
The Dutch Life Sciences Conference 2025 was held on 20 November 2025 at the CORPUS Congress Centre in Oegstgeest, bringing together biotech and medtech companies, academic...